Prothrombin Complex Concentrates Market Analysis & Forecast: 2026-2033

Prothrombin Complex Concentrates Market Size and Share Analysis - 2026 To 2033

The Prothrombin Complex Concentrates Market size is predicted to expand at a CAGR of 10.2% from USD 1,253.4 Mn in 2026 to USD 2,473.7 Mn by 2033. The market growth is mainly attributed to the increasing prevalence of bleeding disorders, increased usage of prothrombin complex concentrates for the rapid reversal of vitamin K antagonist therapy, and the growing demand for effective hemostatic agents in emergency and surgical settings. Analysis of retrospective data from 592 patients administered with 4F-PCC in a fixed dose revealed that in the case of patients taking warfarin, 89% patients have an INR of <2 and <5% require additional dosing, implying efficacy in controlling acute bleeding.

Key Takeaways

• The 4-Factor PCC segment is anticipated to dominate the market with 78.0% share in 2026. This segment is growing because of its better efficacy and fast action against vitamin K antagonist-induced bleeding compared to 3-Factor PCC. The medical guidelines in the Medical Journal of Australia, issued in 2025, recommended the use of 4-Factor PCC in place of 3-Factor PCC for warfarin reversal.
• The acquired coagulation factor deficiency category is expected to lead with a share of 71.0% in 2026. The industry is expanding due to the rising incidence of anticoagulant-related bleeding, trauma, liver disease, and emergency surgeries. In the FARES-II Phase III multicenter randomized trial, published in JAMA, 420 cardiac surgery patients were randomized to receive either 4-factor prothrombin complex concentrate (PCC) or frozen plasma for the treatment of coagulopathic bleeding during cardiac surgery.
• Hospital segment is expected to lead the market with 82.0% share in 2026. The segment's rise is due to the presence of emergency departments, trauma centers, cardiovascular surgery units and intensive care facilities where PCC administration is largely carried out.  In 2025, a study published in the Journal of Acute Care Pharmacotherapy reported that among 82 patients who received 4F-PCC at a Level II Trauma Center, 70% of PCC prescriptions were placed by hospitalists and critical care physicians, while trauma surgery providers placed just 30% of orders.
• North America is projected to lead the Prothrombin Complex Concentrates market in 2026 with an estimated share of 44.5%. The market expansion in this region is attributed to the presence of modern healthcare infrastructure, high prevalence of anticoagulants, higher diagnostic rate for bleeding disorders, and well-established network of specialized centers for treatment. The U.S. Centers for Disease Control and Prevention (CDC) reports that around 33,000 men in the United States have hemophilia, and more than 40% have severe disease that requires prompt coagulation management and blood factor therapy. This enormous patient group is a major driver of the demand for PCC products.

Market Drivers

Rising Burden of Anticoagulant-Associated Bleeding and Cardiovascular Procedures is Driving the Prothrombin Complex Concentrates Market

Increasing incidence of cardiovascular illnesses, atrial fibrillation and rising use of oral anticoagulants are considerably driving the demand for Prothrombin Complex Concentrates (PCCs). With the increasing number of patients requiring urgent anticoagulation reversal, four-factor PCCs are increasingly used by healthcare providers due to their rapid onset and efficacy in life-threatening bleeding and perioperative emergencies.

According to the Centers for Disease Control and Prevention (CDC), around 805,000 heart attacks occur among Americans each year, and 605,000 of those are first-time heart attacks. This highlights the significant burden of cardiovascular disease that necessitates anticoagulant and surgical procedures.

Growing Clinical Preference for Four-Factor PCC and Expanding Treatment Guidelines are Accelerating Market Growth

The growth in the market will be propelled by the rising number of applications of four-factor PCC as the standard treatment modality for vitamin K antagonist reversal and management of hemorrhaging. The growing application of PCC in the field of emergency medicine, at trauma centers and surgery has been spurred by favorable clinical guidelines, better safety profile, and the growing scientific evidence regarding the efficacy of PCCs.

According to the international survey conducted in 2025 and published in the Journal of Thrombosis and Thrombolysis, 94.8% of all healthcare institutions made use of 4-factor PCC for oral anticoagulant reversal. This suggests the prevalence of 4F-PCC use in healthcare institutions.

Current Events and Their Impact on the Prothrombin Complex Concentrates Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Request Free Sample

Why 4-Factor PCC, Acquired Coagulation Factor Deficiency, and Hospitals Dominate the Market?

In terms of types, the 4-Factor PCC segment is expected to capture the highest market share of 78.0% by 2026. The growth in the market can be attributed to the high effectiveness of 4-Factor PCC in reversing vitamin K antagonist-induced hemorrhage, and the increasing demand for 4-Factor PCC over 3-Factor PCC.

Furthermore, the U.S. Food and Drug Administration continue to be devoted to Kcentra and Balfaxar are FDA-approved four-factor prothrombin complex concentrates indicated for urgent reversal of vitamin K antagonist therapy.

In April 2025, Octapharma USA announced the publication of findings from Phase III FARES-II in JAMA. A study showed that non-activated 4F-PCC reduced the relative risk of major bleeding events by more than 40% compared with frozen plasma in patients with excessive bleeding following heart surgery.

Acquired Coagulation Factor Deficiency Leads the Application Segment 

To learn more about this report, Request Free Sample

In terms of application, the acquired coagulation factor deficiency category is expected to hold 71.0% share in 2026. The expansion of the segment is attributed to the high incidence of anticoagulant associated bleeding, trauma cases, liver disease, and emergency surgical operations that require rapid hemostatic correction.

A study published in Critical Care Medicine in January 2025 by experts from NYU Langone Health found that the clinical use of four-factor prothrombin complex concentrate (4F-PCC) greatly exceeded warfarin reversal.

In January 2024, Octapharma announced the commercial launch of Balfaxar, a non-activated four-factor prothrombin complex concentrate intended for the immediate restoration of acquired coagulation factor deficit generated by vitamin K antagonists.

Hospital Segment Dominates End User Share

Based on end user, the hospital segment is predicted to capture the largest market share of 82.0% in 2026. The expansion of the market is attributed to concentration of emergency departments, trauma centers, cardiovascular surgical units and intensive care facilities, where the administration of PCC is primarily undertaken.

In March 2026, a U.S. Level II Trauma Center developed a dedicated 4F-PCC stewardship program, which included updated anticoagulation reversal guidelines and interdisciplinary education to optimize hospital utilization of PCC therapies.

Prothrombin Complex Concentrates Market Trends

• The increased use of PCC in surgeries other than heart surgery is increasing the possibilities of market. The administration of PCC in the patients who were suffering from massive blood loss during non-cardiac surgery has proven through research conducted in July 2025 by the journal name ‘Clinical and Applied Thrombosis/Hemostasis’ that there has been a decrease in postoperative red blood cell transfusions.
• The growing application of PCC in the context of emergency surgery in patients taking oral factor Xa inhibitors. According to a study that appeared in the journal of “Journal of Thrombosis and Haemostasis”, up to 80% of the patients having surgery while on apixaban or rivaroxaban were able to achieve either normal or minimally abnormal surgical hemostasis using PCC.
• PCC is becoming more widely recognized for the treatment of gastrointestinal bleeding. According to a retrospective study published in ACEP Open in April 2025, four-factor PCC successfully led to hemostasis in patients using vitamin K antagonist drugs who have gastrointestinal bleeding or need gastrointestinal procedures done on them.

Regional Insights

To learn more about this report, Request Free Sample

North America Dominates Owing to Advanced Hemostasis Infrastructure and High Burden of Anticoagulant Use

North America is expected to account for an estimated 44.5% Prothrombin Complex Concentrates market share in 2026. Growth in the region is attributed to the presence of advanced infrastructure for trauma and cardiovascular care, widespread use of oral anticoagulants, strong plasma fractionation capabilities, and adoption of evidence-based bleeding management protocols. The presence of leading manufacturers and a large network of tertiary hospitals is also supporting market leadership.

The American Society of Hematology (ASH) 2025 Annual Report states that the Society has over 18,000 members from nearly 120 countries. The United States has the highest concentration of hematologists and coagulation specialists in the world, reflecting the region’s strong expertise and clinical adoption of advanced hemostatic therapies.

In January 2025, the American College of Cardiology (ACC) announced the late-breaking clinical trials selected for presentation at ACC.25, scheduled for March 29–31, 2025, in Chicago.

Asia Pacific Prothrombin Complex Concentrates Market Trends

Asia Pacific is expected to witness the fastest growth during the forecast period. The rise of the region is attributed to the increasing burden of cardiovascular disease, growing healthcare infrastructure, increasing surgical volumes, and improvement in detection and treatment of coagulation disorders. Between 2025 and 2050, cardiovascular disease prevalence is projected to rise by 90.0%, with mortality increasing by 73.4% and DALYs by 54.7%. Annual cardiovascular deaths are expected to reach 35.6 million by 2050, up from 20.5 million in 2025. Growing healthcare expenditure and increased availability to innovative blood products are also boosting the market rise.

In April 2025, Takeda China and Belief BioMed reported that the first gene therapy for hemophilia B in China, BBM-H901 (Dalnacogene Ponparvovec Injection), was approved by the National Medical Products Administration (NMPA) of China. Takeda China will market the therapy in mainland China, Hong Kong and Macau under the strategic collaboration.

U.S. Prothrombin Complex Concentrates Market Trends

The U.S. Prothrombin Complex Concentrates Market is driven by high prevalence of anticoagulant use, upgraded trauma care infrastructure and rising adoption of four-factor PCC in emergency medicine and cardiac surgery. Market expansion is supported by strong clinical evidence and presence of significant producers.

According to the American College of Surgeons (ACS) Trauma Verification, Review, and Consultation (VRC) Program assesses trauma centers across the United States to ensure that they meet stringent standards for resources, readiness, and quality improvement in order to facilitate specialized emergency and surgical care–in the use of PCC products for management of life-threatening bleeding.

Japan Prothrombin Complex Concentrates Market Trends

Japan Prothrombin Complex Concentrates Market is growing due to the increasing aging population, rising prevalence of cardiovascular diseases and strong healthcare infrastructure. The country also scores well on awareness and treatment rates for bleeding diseases.

According to the Ministry of Health, Labour and Welfare (MHLW), Japan had 99,763 centenarians in September 2025, marking the 55th consecutive year of growth in the country's population aged 100 years and above. The increasing longevity of the population is expected to contribute to higher utilization of anticoagulants and associated reversal therapies.

Who are the Major Companies in Prothrombin Complex Concentrates Industry

Some of the major key players in Prothrombin Complex Concentrates Market are Octapharma AG, Nihon Pharmaceutical Co. Ltd., Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc., and Sanquin.

Key News

• In June 2025, Grifols completed the delisting of its German subsidiary Biotest AG, increasing integration of plasma-derived protein operations and strengthening its coagulation and immunology portfolio.
• In May 2025, Kedrion strengthened its engagement with the Plasma Protein Therapeutics Association and continued investments in plasma collection and fractionation capabilities to enhance supply reliability for plasma-derived therapies.

Market Report Scope 

Analyst Opinion

• The expanding global diagnosis and treatment of bleeding disorders is creating sustained demand for coagulation products and specialized hemostatic therapies. According to the World Federation of Hemophilia (WFH) Annual Global Survey 2024, participation reached a record 135 countries, while the global identification of people with hemophilia increased by 6%, reflecting improving awareness and access to treatment worldwide. This trend is expected to support long-term growth in the PCC market.
• Increasing cardiovascular disease burden and widespread anticoagulant use are expected to expand the need for emergency reversal therapies. Nearly 6.7 million U.S. adults are living with heart failure, representing a large population at risk of anticoagulant-associated bleeding and emergency surgical interventions requiring rapid coagulation management.
• Continuous innovation and more than two decades of clinical experience with four-factor PCC products are supporting broader applications beyond warfarin reversal. According to a 2025 review published in Transfusion and Apheresis Science, Octaplex/Balfaxar contains approximately 25 times the concentration of clotting factors found in human plasma, enabling effective treatment across multiple bleeding scenarios and reinforcing the transition toward concentrated coagulation therapies.

Market Segmentation

• By Type (Revenue, USD Mn, 2021-2033)
  • 3-Factor PCC
  • 4-Factor PCC
• By Application (Revenue, USD Mn, 2021-2033)
  • Acquired Coagulation Factor Deficiency
  • Congenital Coagulation Factor Deficiency
  • Others
• By End User (Revenue, USD Mn, 2021-2033)
  • Hospital
  • Ambulatory Surgical Centres
  • Others
• By Region (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  •  Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Hematologists and Coagulation Specialists
• Transfusion Medicine Specialists
• Hospital Pharmacy Directors
• Critical Care and Emergency Medicine Physicians
• Cardiovascular and Trauma Surgeons
• Plasma Fractionation Companies
• Blood Bank and Transfusion Service Providers
• Healthcare Distributors and Procurement Managers
• Regulatory Affairs and Quality Assurance Experts
• Others

Databases

• Bloomberg Terminal
• Thomson Reuters Eikon
• FactSet
• Crunchbase
• Others

Magazines

• Blood
• Hematology Advisor
• Hematology News
• Managed Healthcare Executive
• Pharmaceutical Executive
• MedTech Dive
• Fierce Pharma
• Others

Journals

• Journal of Thrombosis and Haemostasis
• Journal of Thrombosis and Thrombolysis
• Transfusion
• Critical Care Medicine
• Transfusion and Apheresis Science
• Clinical and Applied Thrombosis/Hemostasis
• Journal of Blood Medicine
• American Journal of Hematology
• Others

Newspapers

• Financial Times
• The Wall Street Journal
• Reuters
• Bloomberg News
• The Economic Times
• Business Standard
• Nikkei Asia
• Others

Associations

• World Federation of Hemophilia (WFH)
• American Society of Hematology (ASH)
• International Society on Thrombosis and Haemostasis (ISTH)
• American College of Cardiology (ACC)
• American College of Surgeons (ACS)
• Plasma Protein Therapeutics Association (PPTA)
• National Bleeding Disorders Foundation (NBDF)
• European Hematology Association (EHA)
• Others

Public Domain Sources

• U.S. Food and Drug Administration (FDA)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• ClinicalTrials.gov
• World Health Organization (WHO)
• National Heart, Lung, and Blood Institute (NHLBI)
• Ministry of Health, Labour and Welfare (Japan)
• National Medical Products Administration (China)
• World Federation of Hemophilia Annual Global Survey
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 10 Years